Quick Takeaways
- AVIR - Atea Pharmaceuticals, Inc. has 14 insiders with reported activity on this page.
- No net insider buy/sell flow is currently reported for the last year.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 14 Insiders of Atea Pharmaceuticals, Inc.
- Symbol
- AVIR on Nasdaq
- Location
- Boston, MA
What Changed
- No meaningful buy/sell imbalance is currently visible in the one-year window.
- Activity will update as new Forms 3/4/5 are filed.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsInsider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 13 May 2025.
Buys
$0
Shares: 0
Insiders: 0
Sells
$0
Shares: 0
Insiders: 0
Net
$0
Shares: 0
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Atea Pharmaceuticals, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Jean-Pierre Sommadossi | President, CEO, and Chairman, Director | $22,198,343 | Mixed | 31 Jan 2026 | ||
| Andrea Corcoran | Chief Financial Officer, Executive Vice President, Legal and Secretary | $3,449,970 | Mixed | 11 Mar 2026 | ||
| Franklin M. Berger | Director | $1,526,418 | Mixed | 20 Jun 2025 | ||
| John Vavricka | Chief Commercial Officer | $671,526 | Mixed | 31 Jan 2026 | ||
| Janet Mj Hammond | Chief Development Officer | $575,724 | Mixed | 31 Jan 2026 | ||
| Maria Arantxa Horga | Chief Medical Officer | $437,239 | Mixed | 31 Jan 2026 | ||
| Bruno Lucidi | Director | $419,989 | Mixed | 20 Jun 2025 | ||
| Bruce Polsky | Director | $385,928 | Mixed | 20 Jun 2025 | ||
| Wayne Foster | EVP, Chief Accounting Officer | $363,245 | Mixed | 31 Jan 2026 | ||
| Polly A. Murphy | Director | $360,186 | Mixed | 20 Jun 2025 | ||
| Barbara Gayle Duncan | Director | $279,489 | Mixed | 20 Jun 2025 | ||
| Jerome M. Adams | Director | $279,489 | Mixed | 20 Jun 2025 | ||
| Arthur S. Kirsch | Director | $139,873 | Mixed | 20 Feb 2025 | ||
| Howard Berman | Director | Mixed | 20 Jun 2025 |
Top shareholders of Atea Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13D/G
13F
|
Company |
15%
|
11,950,772
|
$68,238,907 | +$16,302,575 | 31 Mar 2026 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
7.1%
from 13D/G
|
8,491,202
|
$30,313,592 | — | 31 Dec 2025 | |
| BML Investment Partners, L.P. |
13D/G
|
Leonard Braden Michael |
9.9%
|
7,810,000
|
$27,881,700 | +$2,119,466 | 31 Dec 2025 | |
| BML Capital Management, LLC |
13F
|
Company |
9.4%
|
7,490,000
|
$26,739,300 | — | 31 Dec 2025 | |
| Jean-Pierre Sommadossi |
13D/G
3/4/5
|
President, CEO, and Chairman, Director |
10%
|
8,876,453
|
$26,185,536 | $0 | 31 Mar 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
6%
|
4,814,700
|
$17,188,479 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
5.3%
|
4,227,110
|
$15,090,783 | — | 31 Dec 2025 | |
| Bradley Louis Radoff |
13D/G
|
Radoff Bradley Louis |
4%
|
3,380,100
|
$9,971,295 | +$811,250 | 16 Apr 2025 | |
| EcoR1 Capital, LLC |
13D/G
|
— |
4%
|
3,341,653
|
$9,857,876 | $0 | 31 Dec 2024 | |
| Bain Capital Life Sciences Investors, LLC |
13F
|
Company |
3.1%
|
2,485,638
|
$8,873,728 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.3%
|
1,841,001
|
$6,573,860 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.2%
|
1,784,467
|
$6,370,547 | — | 31 Dec 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.7%
|
1,373,946
|
$4,904,865 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
1.7%
|
1,348,294
|
$4,813,410 | — | 31 Dec 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
1.6%
|
1,303,904
|
$4,651,000 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
1.5%
|
1,188,500
|
$4,242,945 | — | 31 Dec 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
1.3%
|
1,059,700
|
$3,783,129 | — | 31 Dec 2025 | |
| Andrea Corcoran |
3/4/5
|
Chief Financial Officer, Executive Vice President, Legal and Secretary |
1%
|
823,576
mixed-class rows
|
$3,449,970 | — | 11 Mar 2026 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.94%
|
745,415
|
$2,661,132 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.88%
|
698,156
|
$2,492,417 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.82%
|
656,075
|
$2,342,187 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.76%
|
607,792
|
$2,169,817 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.7%
|
560,218
|
$1,999,978 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.59%
|
472,522
|
$1,686,904 | — | 31 Dec 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.58%
|
464,787
|
$1,659,289 | — | 31 Dec 2025 | |
| Peapod Lane Capital LLC |
13F
|
Company |
0.55%
|
435,020
|
$1,553,021 | — | 31 Dec 2025 | |
| Franklin M. Berger |
3/4/5
|
Director |
—
mixed-class rows
|
547,697
mixed-class rows
|
$1,526,418 | — | 20 Jun 2025 | |
| CM Management, LLC |
13F
|
Company |
0.45%
|
355,000
|
$1,267,350 | — | 31 Dec 2025 | |
| BANQUE PICTET & CIE SA |
13F
|
Company |
0.43%
|
345,077
|
$1,231,925 | — | 31 Dec 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.31%
|
250,705
|
$895,017 | — | 31 Dec 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.3%
|
242,990
|
$867,474 | — | 31 Dec 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.3%
|
242,840
|
$866,939 | — | 31 Dec 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.3%
|
240,588
|
$858,899 | — | 31 Dec 2025 | |
| HSBC HOLDINGS PLC |
13F
|
Company |
0.3%
|
241,274
|
$855,316 | — | 31 Dec 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.25%
|
198,463
|
$708,513 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.24%
|
192,540
|
$687,368 | — | 31 Dec 2025 | |
| John Vavricka |
3/4/5
|
Chief Commercial Officer |
—
mixed-class rows
|
284,622
mixed-class rows
|
$671,526 | — | 31 Jan 2026 | |
| Opaleye Management Inc. |
13F
|
Company |
0.23%
|
179,815
|
$641,940 | — | 31 Dec 2025 | |
| Auour Investments LLC |
13F
|
Company |
0.22%
|
177,000
|
$631,890 | — | 31 Dec 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.21%
|
170,326
|
$608,064 | — | 31 Dec 2025 | |
| Janet Mj Hammond |
3/4/5
|
Chief Development Officer |
—
mixed-class rows
|
304,665
mixed-class rows
|
$575,724 | — | 31 Jan 2026 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.19%
|
148,400
|
$529,788 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.17%
|
135,794
|
$484,784 | — | 31 Dec 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.16%
|
127,820
|
$456,317 | — | 31 Dec 2025 | |
| Maria Arantxa Horga |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
269,586
mixed-class rows
|
$437,239 | — | 31 Jan 2026 | |
| Bruno Lucidi |
3/4/5
|
Director |
—
mixed-class rows
|
153,950
mixed-class rows
|
$419,989 | — | 20 Jun 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.14%
|
113,585
|
$405,498 | — | 31 Dec 2025 | |
| STRS OHIO |
13F
|
Company |
0.14%
|
113,500
|
$405,195 | — | 31 Dec 2025 | |
| Bruce Polsky |
3/4/5
|
Director |
—
mixed-class rows
|
136,406
mixed-class rows
|
$385,928 | — | 20 Jun 2025 | |
| Wayne Foster |
3/4/5
|
EVP, Chief Accounting Officer |
—
mixed-class rows
|
187,329
mixed-class rows
|
$363,245 | — | 31 Jan 2026 |
Recent Insider Transactions by Companies or Individuals for Atea Pharmaceuticals, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Andrea Corcoran | AVIR | Common Stock | Options Exercise | 7.86% | 60,000 | 823,576 | 11 Mar 2026 | Direct | ||
| Andrea Corcoran | AVIR | Stock Option (Right to Buy) | Options Exercise | 60,000 | 0 | 11 Mar 2026 | Direct | |||
| Jean-Pierre Sommadossi | AVIR | Common Stock | Options Exercise | 64.1% | 300,000 | 767,830 | 03 Feb 2026 | Direct | ||
| Jean-Pierre Sommadossi | AVIR | Stock Option (Right to Buy) | Options Exercise | -100% | -300,000 | 0 | 03 Feb 2026 | Direct | ||
| Maria Arantxa Horga | AVIR | Common Stock | Tax liability | -14.3% | -16,073 | 96,086 | 31 Jan 2026 | Direct | ||
| Maria Arantxa Horga | AVIR | Common Stock | Options Exercise | 84.2% | 51,283 | 112,159 | 31 Jan 2026 | Direct | ||
| Maria Arantxa Horga | AVIR | Stock Option (Right to Buy) | Award | 173,500 | 173,500 | 31 Jan 2026 | Direct | |||
| Maria Arantxa Horga | AVIR | Restricted Stock Units | Options Exercise | -100% | -51,283 | 0 | 31 Jan 2026 | Direct | ||
| John Vavricka | AVIR | Common Stock | Tax liability | -12.3% | -11,570 | 82,594 | 31 Jan 2026 | Direct | ||
| John Vavricka | AVIR | Common Stock | Options Exercise | 80.8% | 42,083 | 94,164 | 31 Jan 2026 | Direct | ||
| John Vavricka | AVIR | Stock Option (Right to Buy) | Award | 119,520 | 119,520 | 31 Jan 2026 | Direct | |||
| John Vavricka | AVIR | Restricted Stock Units | Options Exercise | -100% | -42,083 | 0 | 31 Jan 2026 | Direct | ||
| Janet Mj Hammond | AVIR | Common Stock | Tax liability | -9.97% | -14,136 | 127,665 | 31 Jan 2026 | Direct | ||
| Janet Mj Hammond | AVIR | Common Stock | Options Exercise | 69.3% | 58,050 | 141,801 | 31 Jan 2026 | Direct | ||
| Janet Mj Hammond | AVIR | Stock Option (Right to Buy) | Award | 177,000 | 177,000 | 31 Jan 2026 | Direct | |||
| Janet Mj Hammond | AVIR | Restricted Stock Units | Options Exercise | -100% | -58,050 | 0 | 31 Jan 2026 | Direct | ||
| Wayne Foster | AVIR | Common Stock | Tax liability | -13.3% | -12,132 | 79,329 | 31 Jan 2026 | Direct | ||
| Wayne Foster | AVIR | Common Stock | Options Exercise | 82.4% | 41,333 | 91,461 | 31 Jan 2026 | Direct | ||
| Wayne Foster | AVIR | Stock Option (Right to Buy) | Award | 108,000 | 108,000 | 31 Jan 2026 | Direct | |||
| Wayne Foster | AVIR | Restricted Stock Units | Options Exercise | -100% | -41,333 | 0 | 31 Jan 2026 | Direct | ||
| Andrea Corcoran | AVIR | Common Stock | Tax liability | -2.07% | -16,104 | 763,576 | 31 Jan 2026 | Direct | ||
| Andrea Corcoran | AVIR | Common Stock | Options Exercise | 7.57% | 54,866 | 779,680 | 31 Jan 2026 | Direct | ||
| Andrea Corcoran | AVIR | Stock Option (Right to Buy) | Award | 180,000 | 180,000 | 31 Jan 2026 | Direct | |||
| Andrea Corcoran | AVIR | Restricted Stock Units | Options Exercise | -100% | -54,866 | 0 | 31 Jan 2026 | Direct | ||
| Jean-Pierre Sommadossi | AVIR | Common Stock | Tax liability | -18.5% | -106,093 | 467,830 | 31 Jan 2026 | Direct | ||
| Jean-Pierre Sommadossi | AVIR | Common Stock | Options Exercise | 90.7% | 272,983 | 573,923 | 31 Jan 2026 | Direct | ||
| Jean-Pierre Sommadossi | AVIR | Restricted Stock Units | Options Exercise | -100% | -272,983 | 0 | 31 Jan 2026 | Direct | ||
| Polly A. Murphy | AVIR | Common Stock | Options Exercise | 52.4% | 29,600 | 86,045 | 20 Jun 2025 | Direct | ||
| Polly A. Murphy | AVIR | Restricted Stock Units | Options Exercise | -100% | -29,600 | 0 | 20 Jun 2025 | Direct | ||
| Polly A. Murphy | AVIR | Stock Option (Right to Buy) | Award | 41,200 | 41,200 | 20 Jun 2025 | Direct | |||
| Polly A. Murphy | AVIR | Restricted Stock Units | Award | 29,600 | 29,600 | 20 Jun 2025 | Direct | |||
| Barbara Gayle Duncan | AVIR | Common Stock | Options Exercise | 89.3% | 29,600 | 62,750 | 20 Jun 2025 | Direct | ||
| Barbara Gayle Duncan | AVIR | Restricted Stock Units | Options Exercise | -100% | -29,600 | 0 | 20 Jun 2025 | Direct | ||
| Barbara Gayle Duncan | AVIR | Stock Option (Right to Buy) | Award | 41,200 | 41,200 | 20 Jun 2025 | Direct | |||
| Barbara Gayle Duncan | AVIR | Restricted Stock Units | Award | 29,600 | 29,600 | 20 Jun 2025 | Direct | |||
| Franklin M. Berger | AVIR | Common Stock | Options Exercise | 6.21% | 29,600 | 506,497 | 20 Jun 2025 | Direct | ||
| Franklin M. Berger | AVIR | Restricted Stock Units | Options Exercise | -100% | -29,600 | 0 | 20 Jun 2025 | Direct | ||
| Franklin M. Berger | AVIR | Stock Option (Right to Buy) | Award | 41,200 | 41,200 | 20 Jun 2025 | Direct | |||
| Franklin M. Berger | AVIR | Restricted Stock Units | Award | 29,600 | 29,600 | 20 Jun 2025 | Direct | |||
| Bruce Polsky | AVIR | Common Stock | Options Exercise | 45.1% | 29,600 | 95,206 | 20 Jun 2025 | Direct | ||
| Bruce Polsky | AVIR | Restricted Stock Units | Options Exercise | -100% | -29,600 | 0 | 20 Jun 2025 | Direct | ||
| Bruce Polsky | AVIR | Stock Option (Right to Buy) | Award | 41,200 | 41,200 | 20 Jun 2025 | Direct | |||
| Bruce Polsky | AVIR | Restricted Stock Units | Award | 29,600 | 29,600 | 20 Jun 2025 | Direct | |||
| Jerome M. Adams | AVIR | Common Stock | Options Exercise | 89.3% | 29,600 | 62,750 | 20 Jun 2025 | Direct | ||
| Jerome M. Adams | AVIR | Restricted Stock Units | Options Exercise | -100% | -29,600 | 0 | 20 Jun 2025 | Direct | ||
| Jerome M. Adams | AVIR | Stock Option (Right to Buy) | Award | 41,200 | 41,200 | 20 Jun 2025 | Direct | |||
| Jerome M. Adams | AVIR | Restricted Stock Units | Award | 29,600 | 29,600 | 20 Jun 2025 | Direct | |||
| Bruno Lucidi | AVIR | Common Stock | Options Exercise | 35.6% | 29,600 | 112,750 | 20 Jun 2025 | Direct | ||
| Bruno Lucidi | AVIR | Restricted Stock Units | Options Exercise | -100% | -29,600 | 0 | 20 Jun 2025 | Direct | ||
| Bruno Lucidi | AVIR | Stock Option (Right to Buy) | Award | 41,200 | 41,200 | 20 Jun 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.